“ RYR plus conventional therapy ” exhibited significant lowering effects on serum total cholesterol ( TC ) , low-density lipoprotein cholesterol ( LDL-C ) , and CRP but exhibited no significant effect on systolic BP , diastolic BP , triglycerides ( TG ) , and high-density lipoprotein cholesterol ( HDL-C ) compared with “ placebo plus conventional therapy . ” “
RYR plus conventional therapy ” showed significant lowering effects on systolic BP , TC , LDL-C , and CRP but no effect on diastolic BP , TG , and HDL-C compared with “ placebo plus conventional therapy . ”
No significant difference in BP and lipid profile between “ RYR plus conventional therapy ” and “ statins plus conventional therapy ” was observed .
“ RYR plus statins ” appeared to be more effective in lowering BP , TC , TG , and LDL-C but without a significant difference in HDL-C compared to statins .
No serious adverse events were reported .
The results of this meta- analysis suggested some supportive but limited evidence regarding RYR for hypertension .
ABSTRACT Interest is increasing regarding the potential health effects of red yeast rice ( RYR ) consumption , which is described as a “ natural statin ” in China .
This review aims to evaluate the efficacy of RYR on blood pressure ( BP ) , lipid profile , and C-reactive protein ( CRP ) in treating  hypertension .
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.
AIM Patients with resistant hypertension are at high risk for adverse cardiovascular events . Efforts have been focused on lowering the surrogate endpoint of blood pressure ( BP ) with scant focus on reduction of hard cardiovascular endpoints . However , whether or not intensive lipid lowering is beneficial for reducing the risk of cardiovascular events in this high-risk cohort is not known . METHODS AND RESULTS We evaluated 10 001 patients with coronary artery disease and a low-density lipoprotein cholesterol level < 130 mg/dL , r and omized to atorvastatin 80 vs. 10 mg , enrolled in the Treating to New Targets trial . Treatment-resistant hypertension ( TRH ) was defined as BP ≥140 mmHg despite being on three antihypertensive agents or < 140 mmHg on four or more agents . Subjects were followed up for a median duration of 4.9 years . The primary outcome was major cardiovascular events ( composite of non-fatal myocardial infa rct ion ( MI ) , fatal coronary heart disease ( CHD ) , resuscitated cardiac arrest , and stroke ) . Among the 10 001 patients in the trial , 1112 ( 11.1 % ) patients had TRH . Atorvastatin 80 mg , in patients with TRH , was associated with a significant reduction in the risk of the primary outcome ( HR = 0.70 ; 95 % CI 0.52 - 0.93 ; P = 0.01 ) , driven largely by a significant reduction in CHD deaths ( HR = 0.55 ; 95 % CI 0.32 - 0.97 ; P = 0.04 ) . In addition , atorvastatin 80 mg was associated with a reduction in major coronary events ( HR = 0.67 ; 95 % CI 0.49 - 0.93 ; P = 0.02 ) , and any cardiovascular or coronary event and with a trend ( P = 0.05 ) towards reduction in all-cause mortality ( HR = 0.68 ; 95 % CI 0.46 - 1.01 ) when compared with atorvastatin 10 mg . The results were similar when analysed for the two separate components of the TRH cohort . CONCLUSION In subjects with TRH , intensive lipid lowering with atorvastatin 80 mg is associated with a significant reduction in cardiovascular events
“ RYR plus conventional therapy ” exhibited significant lowering effects on serum total cholesterol ( TC ) , low-density lipoprotein cholesterol ( LDL-C ) , and CRP but exhibited no significant effect on systolic BP , diastolic BP , triglycerides ( TG ) , and high-density lipoprotein cholesterol ( HDL-C ) compared with “ placebo plus conventional therapy . ” “
RYR plus conventional therapy ” showed significant lowering effects on systolic BP , TC , LDL-C , and CRP but no effect on diastolic BP , TG , and HDL-C compared with “ placebo plus conventional therapy . ”
No significant difference in BP and lipid profile between “ RYR plus conventional therapy ” and “ statins plus conventional therapy ” was observed .
“ RYR plus statins ” appeared to be more effective in lowering BP , TC , TG , and LDL-C but without a significant difference in HDL-C compared to statins .
No serious adverse events were reported .
The results of this meta- analysis suggested some supportive but limited evidence regarding RYR for hypertension .
ABSTRACT Interest is increasing regarding the potential health effects of red yeast rice ( RYR ) consumption , which is described as a “ natural statin ” in China .
This review aims to evaluate the efficacy of RYR on blood pressure ( BP ) , lipid profile , and C-reactive protein ( CRP ) in treating  hypertension .